-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels' ELISpot Platform: A New Perspective on Cellular Immunity
Author:
InnoModels
Release time:
2024-04-19
With the continuous development of biotechnology, people's understanding of cellular immunity mechanism is getting deeper and deeper. As a highly sensitive and specific immunoassay technology, the InnoModels Biotechnology ELISpot platform provides researchers and clinicians with a new perspective to explore cellular immune responses in depth.
1. High sensitivity and specificity
The ELISpot platform employs an enzyme-linked immunospot assay that accurately detects cytokines secreted by individual cells. This high sensitivity allows the platform to accurately capture antigen-specific T cell responses even at very low antigen concentrations. In addition, due to its direct targeting of cell-secreted cytokines, ELISpot technology can accurately reflect the activity of antigen-specific T cells, avoiding the interference of other non-specific responses and ensuring the accuracy of the test results.
2. High-throughput processing capability
InnoModels Bio's ELISpot platform is equipped with high-throughput processing capability, which can test multiple samples at the same time, greatly improving work efficiency. This efficient processing capability allows researchers to process a large number of samples in a short period of time, speeding up research progress and providing powerful support for research in the fields of disease diagnosis, vaccine development and drug screening.

3. Intuitive visualization of test results
ELISpot's results are presented in the form of spots on the membrane, which makes the interpretation of the results simple and clear. Researchers can directly observe the number and distribution of spots on the membrane to determine the activity and number of antigen-specific T cells in the sample. This intuitive presentation not only improves the convenience of results interpretation, but also helps researchers better understand the dynamics of the cellular immune response.
4. Accurate quantitative analysis
In addition to the visual presentation of the test results, the ELISpot platform of InnoModels Biotechnology has the ability to perform accurate quantitative analysis. By counting and statistically analyzing the number of spots on the membrane, the number of antigen-specific T-cells can be accurately quantified. This quantitative analysis capability provides researchers with more detailed data support and helps them to better understand the mechanism and regulation of cellular immune response.
Summary
As an advanced immunoassay technology, InnoModels' ELISpot platform features high sensitivity, high specificity, high throughput, intuitive visualization, and precise quantification. These features make the platform have a wide range of application prospects in the fields of immunology research, disease diagnosis, vaccine development and drug screening. With the continuous progress of science and technology and the deepening of people's understanding of cellular immunity mechanisms, the ELISpot platform of InnoModels Biotechnology is expected to play an important role in more fields, and contribute new strength to the development of human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd